Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,434 questions in 139 reviews · Kidney and Transplant
current versionsNo studies 504 · 20.7%Ungraded 40 · 1.6%Very low 611 · 25.1%Low 790 · 32.5%Moderate 414 · 17%High 75 · 3.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) Residual kidney function (12 months) · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | no estimate extracted | 1 study · 60 participants | Moderate |
Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) Anuria · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | RR 1.15 [0.41, 3.26] | 1 study · 60 participants | Moderate |
Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) Cardiovascular events (non‐fatal) · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | RR 1.33 [0.33, 5.45] | 1 study · 60 participants | Moderate |
Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) Serum potassium · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | no estimate extracted | 1 study · 42 participants | Moderate |
Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) Systolic BP · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | no estimate extracted | 1 study · 42 participants | Moderate |
Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) Diastolic BP · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | no estimate extracted | 1 study · 42 participants | Moderate |
Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) Cough · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | RR 1.56 [0.24, 10.05] | 1 study · 60 participants | Moderate |
Angiotensin receptor blockers (ARBs) vs conventional therapy Residual kidney function (≥ 12 months) · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | no estimate extracted | 3 studies · 110 participants | Moderate |
Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) Hyperkalaemia · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | RR 1.23 [0.35, 4.4] | 2 studies · 144 participants | Moderate |
Angiotensin receptor blockers (ARBs) vs conventional therapy Residual kidney function (12 months) · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | no estimate extracted | 1 study · 44 participants | Moderate |
Angiotensin receptor blockers (ARBs) vs conventional therapy Residual kidney function (24 months) · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | no estimate extracted | 2 studies · 66 participants | Moderate |
Angiotensin receptor blockers (ARBs) vs conventional therapy Urinary protein excretion · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | no estimate extracted | 2 studies · 66 participants | Low |
Angiotensin receptor blockers (ARBs) vs conventional therapy Kt/V · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | no estimate extracted | 2 studies · 76 participants | Moderate |
Angiotensin receptor blockers (ARBs) vs conventional therapy Weekly creatinine clearance · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | no estimate extracted | 3 studies · 110 participants | Low |
Angiotensin receptor blockers (ARBs) vs conventional therapy Systolic BP · patients receiving PD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney… (2014) · Cochrane | no estimate extracted | 3 studies · 110 participants | Moderate |
Intervention NR Death · Kidney transplant recipients Belatacept for kidney transplant recipients (2014) · Cochrane | no estimate extracted | 4 studies · 1516 participants | High |
Intervention NR Loss of kidney transplant · Kidney transplant recipients Belatacept for kidney transplant recipients (2014) · Cochrane | no estimate extracted | 4 studies · 1516 participants | High |
Intervention NR Acute rejection · Kidney transplant recipients Belatacept for kidney transplant recipients (2014) · Cochrane | no estimate extracted | 4 studies · 1516 participants | High |
Intervention NR Chronic kidney scarring · Kidney transplant recipients Belatacept for kidney transplant recipients (2014) · Cochrane | no estimate extracted | 3 studies · 1350 participants | High |
Intervention NR Malignancy · Kidney transplant recipients Belatacept for kidney transplant recipients (2014) · Cochrane | no estimate extracted | 4 studies · 1516 participants | Moderate |
Intervention NR PTLD · Kidney transplant recipients Belatacept for kidney transplant recipients (2014) · Cochrane | no estimate extracted | 4 studies · 1516 participants | Moderate |
Intervention NR New onset diabetes · Kidney transplant recipients Belatacept for kidney transplant recipients (2014) · Cochrane | no estimate extracted | 4 studies · 1049 participants | Moderate |
Intervention NR Delayed graft function · Kidney transplant recipients Belatacept for kidney transplant recipients (2014) · Cochrane | no estimate extracted | 2 studies · 1209 participants | High |
Intervention NR Presence of donor specific antibodies · Kidney transplant recipients Belatacept for kidney transplant recipients (2014) · Cochrane | no estimate extracted | 2 studies · 1209 participants | Moderate |
Intervention NR Major cardiovascular events · adults with chronic kidney disease HMG CoA reductase inhibitors (statins) for dialysis patients (2013) · Cochrane | RR 0.95 [0.88, 1.03] | 4 studies · 7804 participants | High |
Intervention NR All‐cause mortality · adults with chronic kidney disease HMG CoA reductase inhibitors (statins) for dialysis patients (2013) · Cochrane | RR 0.96 [0.9, 1.02] | 13 studies · 4705 participants | Moderate |
Intervention NR Cardiovascular mortality · adults with chronic kidney disease HMG CoA reductase inhibitors (statins) for dialysis patients (2013) · Cochrane | RR 0.94 [0.84, 1.06] | 13 studies · 4627 participants | Moderate |
Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment All symptomatic CMV disease · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 6 studies · 288 participants | Low |
Pre‐emptive medication vs prophylaxis Acute rejection · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 6 studies · 693 participants | Low |
Pre‐emptive medication vs prophylaxis Leucopenia · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 6 studies · 729 participants | Moderate |
Pre‐emptive medication vs prophylaxis D+/R‐ serostatus: symptomatic CMV · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 2 studies · 39 participants | Very low |
Pre‐emptive medication vs prophylaxis D+ or D‐/R+ serostatus: symptomatic CMV · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 2 studies · 93 participants | Very low |
Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment CMV organ involvement · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 5 studies · 217 participants | Low |
Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment Acute rejection · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 3 studies · 185 participants | Low |
Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment All‐cause mortality · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 3 studies · 176 participants | Low |
Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment Graft loss · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 1 study · 36 participants | Very low |
Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment Leucopenia · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 2 studies · 114 participants | Low |
Pre‐emptive medication vs prophylaxis All symptomatic CMV disease · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 7 studies · 753 participants | Low |
Pre‐emptive medication vs prophylaxis All‐cause mortality · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 7 studies · 753 participants | Low |
Pre‐emptive medication vs prophylaxis Graft loss · solid organ transplant recipients with CMV viraemia Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ… (2013) · Cochrane | no estimate extracted | 7 studies · 753 participants | Low |
Summary of findings: Tripterygium wilfordii Hook F (TwHF) vs no TwHF Complete remission ( · patients with primary nephrotic syndrome Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome (2013) · Cochrane | RR 1.46 [1.18, 1.8] | 4 studies · 293 participants | Low |
Summary of findings: Tripterygium wilfordii Hook F (TwHF) vs no TwHF Partial remission ( · patients with primary nephrotic syndrome Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome (2013) · Cochrane | RR 0.77 [0.49, 1.21] | 4 studies · 293 participants | Low |
Summary of findings: Tripterygium wilfordii Hook F (TwHF) vs no TwHF Complete or partial remission ( · patients with primary nephrotic syndrome Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome (2013) · Cochrane | RR 1.26 [1.1, 1.44] | 4 studies · 293 participants | Low |
Summary of findings: Tripterygium wilfordii Hook F vs prednisone Complete remission ( · patients with primary nephrotic syndrome Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome (2013) · Cochrane | RR 1.09 [0.83, 1.43] | 4 studies · 223 participants | Low |
Summary of findings: Tripterygium wilfordii Hook F vs prednisone Partial remission ( · patients with primary nephrotic syndrome Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome (2013) · Cochrane | RR 1.07 [0.69, 1.65] | 4 studies · 223 participants | Low |
Summary of findings: Tripterygium wilfordii Hook F vs prednisone Complete or partial remission ( · patients with primary nephrotic syndrome Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome (2013) · Cochrane | RR 1.05 [0.92, 1.2] | 4 studies · 223 participants | Low |
Intervention NR Complete remission ( · patients with primary nephrotic syndrome Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome (2013) · Cochrane | RR 1.06 [0.82, 1.37] | 2 studies · 114 participants | Low |
Intervention NR Partial remission ( · patients with primary nephrotic syndrome Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome (2013) · Cochrane | RR 1.02 [0.46, 2.29] | 2 studies · 114 participants | Low |
Intervention NR Complete or partial remission ( · patients with primary nephrotic syndrome Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome (2013) · Cochrane | RR 1.05 [0.9, 1.23] | 2 studies · 114 participants | Low |
Tacrolimus vs cyclosporin Mortality Mortality at latest · Lung transplant recipients Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients (2013) · Cochrane | RR 1.06 [0.75, 1.49] | 3 studies · 413 participants | Low |